Companies: 10,795·Total market cap: $144.5T
Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc

AVDLNASDAQHealthcare
$21.64
+$0.00(+0.00%)
Market Cap$2.1B
P/E Ratio
52W High$23.57
52W Low$6.38
Overview

Avadel Pharmaceuticals plc (AVDL) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · AVDL · as of Jun 8, 2026

Key Statistics

EPS (TTM)$0.00avdl eps ttm · avdl earnings per shareEarnings history
PE Ratio (TTM)108200.0×avdl pe ratio ttm · avdl price to earningsPE Ratio deep dive
Revenue (TTM)$248.5Mavdl revenue ttm · avdl annual revenueFull revenue history
Dividend YieldNo Dividenddoes avdl pay dividends · avdl dividend yieldDividend history
Shares Outstanding95.1Mavdl shares outstanding · avdl floatShares outstanding history
Next EarningsTBAavdl earnings date · avdl next earningsEarnings history

Financial Snapshot

Full Financials
FY 2024Revenue$169.1M▲ +504.79% YoY
202220232024
avadel pharmaceuticals plc revenue · avdl revenue 2024
FY 2024Net Income-$48.8M▲ +69.53% YoY
202220232024
avadel pharmaceuticals plc net income · avdl profit 2024
FY 2024EPS$-0.51▲ +74.50% YoY
202220232024
avdl eps · avadel pharmaceuticals plc earnings per share 2024
TTM:Revenue: $248.5MNet Income: -$278000.00EPS: $0.00View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy14 analystsis avdl a buy · avdl analyst rating
Strong Buy
0
Buy
8
Hold
6
Sell
0
Strong Sell
0
12-Month Price Target
$18.50Low
$21.64Current
$21.43Avg Target0.97% downside
$30.00High
avdl price target · avdl 12 month forecast

Total: 14 · Buy rate: 57.1%

The AVDL analyst consensus is Buy, based on ratings from 14 Wall Street analysts over the past 3 months. The average 12-month price target is $21.43, representing -0.97% downside from the current price of $21.64.

Stock Performance

Full History
1D+0.00%
1W+0.00%
1M+0.00%
3M+1.03%
YTD+0.56%
1Y+144.80%
5Y+114.90%

About Avadel Pharmaceuticals plc

CEOGregory J. Divis Jr.
IPO DateJun 7, 1996
Employees188
CountryIE
Websiteavadel.com

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for …

what is avadel pharmaceuticals plc · avdl stock overview · avadel pharmaceuticals plc company profile · who is avadel pharmaceuticals plc ceo · avdl NASDAQ · avadel pharmaceuticals plc headquarters · avadel pharmaceuticals plc business segments

About Stock Overview & Key Data

Avadel Pharmaceuticals plc (AVDL) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry, listed on NASDAQ since Jun 7, 1996. As of the latest trading session, AVDL stock price is $21.64, with a market capitalization of $2.1B. The stock has returned +144.80% over the past 12 months and +0.56% year-to-date.

According to 14 Wall Street analysts, the consensus rating for Avadel Pharmaceuticals plc stock is Buy, with an average 12-month price target of $21.43. In fiscal year 2024, Avadel Pharmaceuticals plc reported revenue of $169.1M and net income of -$48.8M. For detailed data — including Avadel Pharmaceuticals plc revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Avadel Pharmaceuticals plc (AVDL) stock price is $21.64. The stock is traded on NASDAQ under the ticker symbol AVDL. The 52-week range is $6.38 – $23.57.

AVDL stock priceAVDL quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice